Skip to main content

Table 2 Adverse Events in ≥ 20% of Study Population

From: Long-term safety of Mometasone Furoate administered via a dry powder inhaler in children: Results of an open-label study comparing Mometasone Furoate with Beclomethasone Dipropionate in children with persistent asthma

Adverse Event, n (%)

MF-DPI

200 μg QD AM

(n = 78)

MF-DPI

100 μg BID

(n = 74)

BDP

168 μg BID

(n = 81)

Allergy

22 (28)

11 (15)

20 (25)

Fever

18 (23)

20 (27)

26 (32)

Headache

33 (42)

27 (36)

25 (31)

Viral infection

27 (35)

26 (35)

29 (36)

Nasal congestion

7 (9)

17 (23)

11 (14)

Pharyngitis

26 (33)

25 (34)

25 (31)

Rhinitis

29 (37)

20 (27)

22 (27)

Sinusitis

15 (19)

15 (20)

11 (14)

Upper respiratory tract infection

38 (49)

35 (47)

41 (51)

  1. BID = twice daily; BDP = beclomethasone dipropionate; MF-DPI = mometasone furoate administered via a dry powder inhaler; QD AM = once daily in the morning.